57 completed, 2 terminated, 2 unknown, 2 withdrawn. 65 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 65 | Completed 57, Terminated 2, Unknown 2, Withdrawn 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 9 | Completed 7, Unknown 1, Withdrawn 1 |
Follow Dengue: new trials by email Literature Review of Dengue trials Research Report on Dengue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant - Randomised Clinical Trial, Double Blind | Phase 1 | Not yet recruiting | VLP Therapeutics | 42 | 2027-01-04 | 2026-09-21 |
| Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection rDEN2delta30-7169 - Healthy Volunteers, Dengue | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2026-08-07 | 2026-10-22 |
| Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients CPLE, Placebo - Dengue Fever | Phase 1 / Phase 2 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 184 | 2024-06-01 | 2025-04-25 |
| Homologous Re-infection With Dengue 1 or Dengue 3 Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC), Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC) - Dengue | Phase 1 | Completed | State University of New York - Upstate Medical University | 9 | 2023-10-30 | 2024-11-13 |
| Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model AT-752, Placebo Comparator - Dengue | Phase 1 | Terminated | Atea Pharmaceuticals, Inc. | 5 | 2022-04-22 | 2023-04-21 |
| Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4) Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose, Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose - Homologous Rechallenge - Dengue | Phase 1 | Completed | University of Maryland, Baltimore | 20 | 2022-02-28 | 2025-04-17 |
| A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus LD vehicle-GNP, LD PepGNP-Dengue, HD vehicle-GNP - Dengue | Phase 1 | Completed | Gylden Pharma Ltd | 26 | 2021-08-02 | 2022-12-05 |
| Study of AT-752 in Healthy Subjects AT-752, Placebo - Dengue | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 65 | 2021-03-09 | 2022-10-17 |
| ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC) Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) - Dengue | Phase 1 | Completed | University of Maryland, Baltimore | 10 | 2020-11-30 | 2025-02-27 |
| Dengue 3 Human Infection Model (DENV-3) Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC) - Dengue | Phase 1 | Completed | State University of New York - Upstate Medical University | 9 | 2020-08-03 | 2024-04-11 |
| Metformin in Dengue With Obesity Metformin - Dengue, Viral Infection | Phase 1 / Phase 2 | Completed | Oxford University Clinical Research Unit, Vietnam | 120 | 2020-07-27 | 2023-08-31 |
| A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers AV-1, Placebo - Healthy Volunteers | Phase 1 | Completed | AbViro LLC | 42 | 2020-02-04 | 2022-10-31 |
| Safety Study of Dengushield in Healthy Adults Dengushield 1 mg/kg (Cohort 1) intravenous, Dengushield 3 mg/kg (Cohort 2) intravenous, Placebo 3 mg/kg (Cohort 2) intravenous - Phase 1, Dengue | Phase 1 | Completed | Serum Institute of India Pvt. Ltd. | 40 | 2019-03-22 | 2020-02-18 |
| Expansion of a Dengue-1 Live Virus Human Challenge Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) - Dengue | Phase 1 | Completed | State University of New York - Upstate Medical University | 9 | 2019-03-11 | 2024-04-11 |
| Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Celgosivir, Modipafant 50mg, Placebo - Dengue Fever | Phase 1 / Phase 2 | Withdrawn | Singapore General Hospital | 2018-12-01 | 2020-03-23 | |
| Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge TetraVax-DV-TV003 (TV003), rDEN2Δ30-7169 (DENV-2), rDEN3Δ30 (DENV-3) - Dengue | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 64 | 2017-11-28 | 2020-01-18 |
| Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30 TetraVax-DV-TV005, rDEN3Δ30, Placebo - Dengue | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2016-08-01 | 2018-03-08 |
| Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution - Viral Infection | Phase 1 | Terminated | Emergent BioSolutions | 7 | 2016-05-27 | 2024-03-18 |
| Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age TetraVax-DV TV005, Placebo - Dengue | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 28 | 2016-02-01 | 2018-04-02 |
| TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant TDENV-PIV, TDENV-F17, Placebo - Dengue | Phase 1 | Withdrawn | U.S. Army Medical Research and Development Command | 2016-01-01 | 2017-04-12 |
Showing 20 of 65. Sign in to see all of them.
Severe Dengue (16) · Virus Diseases (7) · Flavivirus Infections (5) · Arbovirus Infections (2) · Flaviviridae Infections (2) · Hemorrhagic Fevers, Viral (2) · RNA Virus Infections (2) · Obesity (1) · Overweight (1)
Infections (65) · Mosquito-Borne Diseases (65) · Vector Borne Diseases (65) · Arbovirus Infections (63) · Flaviviridae Infections (63) · Hemorrhagic Fevers, Viral (63) · RNA Virus Infections (63) · Flavivirus Infections (60) · Virus Diseases (58) · Body Weight (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1) · Overnutrition (1) · Pathological Conditions, Signs and Symptoms (1)
Aluminum Hydroxide (5) · Vaccines (5) · AT-752 (2) · Sodium Chloride (2) · celgosivir (2) · Biological Products (1) · Chickenpox Vaccine (1) · Chloroquine (1) · Dengue Vaccines (1) · Injections (1) · Metformin (1) · Serogroup (1) · Solutions (1) · Vaccines, Attenuated (1) · balapiravir (1)
National Institute of Allergy and Infectious Diseases (NIAID) (29) · U.S. Army Medical Research and Development Command (12) · State University of New York - Upstate Medical University (3) · Atea Pharmaceuticals, Inc. (2) · Emergent BioSolutions (2) · Singapore General Hospital (2) · University of Maryland, Baltimore (2) · AbViro LLC (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Fr Muller Homoeopathic Medical College (1) · Gylden Pharma Ltd (1) · Hawaii Biotech, Inc. (1) · Hoffmann-La Roche (1) · Inviragen Inc. (1) · Merck Sharp & Dohme LLC (1)
United States (49) · Thailand (3) · Australia (2) · Singapore (2) · Vietnam (2) · Bangladesh (1) · Brazil (1) · Colombia (1) · Puerto Rico (1) · Switzerland (1)
Anna Durbin, MD (25) · Beth Kirkpatrick, MD (3) · Kristen Pierce, MD (3) · Stephen J Thomas, MD (3) · Benedito AL Fonseca, PhD (1) · Beth-Ann Coller, PhD (1) · Blaise Genton, Prof (1) · Camila D Odio, M.D. (1) · Charmagne Beckett, MD (1) · Clemente Diaz, MD (1) · Ivan D Velez, MD, Ph.D. (1) · Janine R Danko, MD (1) · Jenny Low, Dr (1) · Kawsar Talaat, MD (1)
PMID 26383952, PMID 25801652, PMID 26424605, PMID 26458804, PMID 32394880, PMID 32572470, PMID 37971871, PMID 42253092, PMID 18337339, PMID 21111785, PMID 21208923, PMID 21813857, PMID 22807519, PMID 23329850, PMID 24877997, PMID 25087476, PMID 25791116, PMID 26794905, PMID 26908742, PMID 27509020, PMID 28481883, PMID 28719287, PMID 29363446, PMID 29512481, PMID 30010906, PMID 32342848, PMID 32966573, PMID 33083561, PMID 33597521, PMID 34031380, PMID 35939501, PMID 36288280, PMID 38408457, PMID 38526047, PMID 38679035, PMID 40591696, PMID 42132421